Interleukin-2 (IL-2) activates both immunosuppressive regulatory T cells (Tregs) and inflammatory cells, and low dose IL-2 therapy has been shown to effectively expand Tregs. However, this therapeutic ...
The use of interleukin-2 (IL-2)-directed therapies has been associated with systemic toxicities, regulatory T cell (Treg) activation and limited efficacy so far. Researchers from Regeneron ...
LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of potentially best-in-class IL-2 therapeutics, today shared ...
Interleukin-2 (IL-2) is a cytokine, a type of immune system signaling molecule, that plays a crucial role in the body's defense against microbial infections and distinguishing between self and ...
LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of best-in-class IL-2 therapeutics, today announced dosing ...
Only systemic treatment for relapsed or refractory (r/r) CTCL to target the IL-2 receptor on malignant T-cells and Tregs LYMPHIR is expected to launch within the next five months LYMPHIR's approval ...
Development of a CCR8 monoclonal antibody to block CCR8 signaling and to abolish the immunosuppressive function of Treg for the treatment of cancers. Investigating the novel CD16A and epidermal growth ...
A GIF showing a protein mimicking IL-2 binding to IL-2 receptors, then changing shape in response to an effector molecule, which forces it off of one of the receptors. A protein mimicking IL-2 called ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results